Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Recipient : Intract Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease
Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Recipient : Intract Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients
Details : French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
Brand Name : BIO101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : Biophytis
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respi...
Brand Name : BIO101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2020
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Biophytis
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?